nach oben

Current Treatment Options in Neurology

Erschienen in:

01.08.2019 | Neurologic Ophthalmology and Otology (R Shin and D Gold, Section Editors)

Treatment Strategies for Neuroretinitis: Current Options and Emerging Therapies

verfasst von: Aaron M. Fairbanks, MD, Matthew R. Starr, MD, John J. Chen, MD, PhD, M. Tariq Bhatti, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

To explore and critically appraise the published data on the current and emerging treatment modalities for neuroretinitis.

Recent findings

The optimum treatment strategy for neuroretinitis due to Bartonella henselae in immunocompetent individuals is not clear and a matter of debate. The role of systemic corticosteroids in infectious neuroretinitis and the optimum immunosuppressive regimen for use in recurrent idiopathic neuroretinitis also remains ill defined.

Summary

There is no class 1 evidence to support a specific treatment strategy for neuroretinitis. For uncomplicated B. henselae–associated neuroretinitis in immunocompetent patients, initiation of antibiotic and corticosteroid therapy remains controversial. In patients with severe vision loss and/or moderate to severe systemic symptoms, a 4- to 6-week regimen of doxycycline or azithromycin with rifampin may provide some benefit. The routine use of systemic corticosteroids in infectious neuroretinitis is not recommended. Targeted antimicrobial agents should be instituted in cases of neuroretinitis due to specific infectious etiologies (e.g., syphilis, Lyme disease, tuberculosis). Azathioprine may be beneficial in cases of recurrent idiopathic neuroretinitis. There is a need for collaborative, multicenter prospective studies to provide definitive guidelines regarding the use of antibiotics and corticosteroids and to evaluate future therapies in infectious and recurrent idiopathic neuroretinitis.

Nur mit Berechtigung zugänglich

•• Abdelhakim A, Rasool N. Neuroretinitis: a review. Curr Opin Ophthalmol. 2018;29(6):514–9. The most up-to-date review on all aspects of neuroretinitis including the different etiologies as well as treatment options. The authors discuss the pros and cons of antibiotics vs no antibiotics for the management of cat scratch neuroretinitis.CrossRef

Pahor D. Leber’s idiopathic stellate neuroretinitis. Can J Ophthalmol. 2001;36(6):347–9.PubMedCrossRef

Gass JD. Diseases of the optic nerve that may simulate macular disease. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(5):763–70.PubMed

Kitamei H, Suzuki Y, Takahashi M, Katsuta S, Kato H, Yokoi M, et al. Retinal angiography and optical coherence tomography disclose focal optic disc vascular leakage and lipid-rich fluid accumulation within the retina in a patient with leber idiopathic stellate neuroretinitis. J Neuroophthalmol. 2009;29(3):203–7.PubMedCrossRef

Maitland CG, Miller NR. Neuroretinitis. Arch Ophthalmol. 1984;102(8):1146–50.PubMedCrossRef

Celiker H, Kazokoglu H, Eraslan M, Cerman E, Karabas L. Bartonella henselae neuroretinitis in patients without cat scratch. Jpn J Infect Dis. 2018;71(6):397–401.PubMedCrossRef

Narayan SK, Kaliaperumal S, Srinivasan R. Neuroretinitis, a great mimicker. Ann Indian Acad Neurol. 2008;11(2):109–13.PubMedPubMedCentralCrossRef

Vaphiades MS. Rocky Mountain Spotted Fever as a cause of macular star figure. J Neuroophthalmol. 2003;23(4):276–8.PubMedCrossRef

Reche-Sainz JA, Gracia Garcia-Miguel MT, Perez-Jacoiste MA. Papillitis and neuroretinitis of tuberculous etiology. Arch Soc Esp Oftalmol. 2019.

10.

Fusco R, Magli A, Guacci P. Stellate maculopathy due to Salmonella typhi. A case report. Ophthalmologica. 1986;192(3):154–8.PubMedCrossRef

11.

Guliani BP, Kumar S, Chawla N, Mehta A. Neuroretinitis as presenting and the only presentation of Lyme disease: diagnosis and management. Indian J Ophthalmol. 2017;65(3):250–2.PubMedPubMedCentralCrossRef

12.

Shoeibi N, Hosseini SM, Bayani R. Toxoplasmosis neuroretinitis: a case report. Iran Red Crescent Med J. 2016;18(4):e33115.PubMedPubMedCentralCrossRef

13.

Basumatary LJ, Das S, Das M, Goswami M, Kayal AK. Leptospirosis presenting as neuroretinitis. J Neurosci Rural Pract. 2012;3(2):224–6.PubMedPubMedCentralCrossRef

14.

Besirli CG, Elner SG. Retinal vasculitis in Toxocara canis neuroretinitis. J Ophthalmic Inflamm Infect. 2013;3(1):5.PubMedPubMedCentralCrossRef

15.

Choi RY, Lauer A, Rosenbaum JT. Molecular diagnosis and ocular imaging of varicella zoster virus associated neuroretinitis. Am J Ophthalmol Case Rep. 2018;11:146–8.PubMedPubMedCentralCrossRef

16.

Hsia YC, Chin-Hong PV, Levin MH. Epstein-Barr virus neuroretinitis in a lung transplant patient. J Neuroophthalmol. 2017;37(1):43–7.PubMedPubMedCentralCrossRef

17.

Johnson BL, Wisotzkey HM. Neuroretinitis associated with herpes simplex encephalitis in an adult. Am J Ophthalmol. 1977;83(4):481–9.PubMedCrossRef

18.

Sivakumar RR, Prajna L, Arya LK, Muraly P, Shukla J, Saxena D, et al. Molecular diagnosis and ocular imaging of West Nile virus retinitis and neuroretinitis. Ophthalmology. 2013;120(9):1820–6.PubMedCrossRef

19.

Panday A, Sandy S, King D, Ramdeen S. A case of suspected symptomatic Zika Neuroretinitis. IDCases. 2017;9:104–5.PubMedPubMedCentralCrossRef

20.

Davila PJ, Toledo A, Ulloa-Padilla JP, Izquierdo NJ, Emanuelli A. Unilateral neuroretinitis as a late-onset manifestation of the chikungunya fever: a case series. Retin Cases Brief Rep. 2017:1.

21.

Ray S, Gragoudas E. Neuroretinitis. Int Ophthalmol Clin. 2001;41(1):83–102.PubMedCrossRef

22.

Fine M, Flocks M. Bilateral acute neuroretinitis with sarcoidosis treated with corticotropin and cortisone. AMA Arch Ophthalmol. 1953;50(3):358–62.PubMedCrossRef

23.

Matsuda A, Chin S, Ohashi T. A case of neuroretinitis associated with long-standing polyarteritis nodosa. Ophthalmologica. 1994;208(3):168–71.PubMedCrossRef

24.

Aigbe N, Bennouk Y, Madzou M, El Asri F, Chergui K, Brahime F, et al. Bilateral neuroretinitis secondary to Takayasu’s arteritis in a young girl. J Fr Ophtalmol. 2015;38(5):e89.PubMedCrossRef

25.

Santra G, Das I. Systemic lupus erythematosus presenting as neuroretinitis. J Assoc Physicians India. 2015;63(10):77–8.PubMed

26.

Pellegrini F, Interlandi E, Prosdocimo G. Vogt-Koyanagi-Harada disease presenting as unilateral neuroretinits. Neuroophthalmology. 2018;42(1):11–6.PubMedCrossRef

27.

Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. J Neuroophthalmol. 2011;31(1):58–68.CrossRefPubMed

28.

Saito M, Saito W, Kanda A, Ohguro H, Ishida S. A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and alpha-enolase. BMC Ophthalmol. 2014;14:5.PubMedPubMedCentralCrossRef

29.

• Lee AR, El-Dairi MA. Anti-myelin oligodendrocyte glycoprotein optic neuritis or neuroretinitis? JAMA Ophthalmol. 2018;136(10):e182928. This case report highlights a patient with neuroretinitis who was discovered to have anti-MOG antibodies, indicating that anti-MOG ought to be excluded before labeling patients with idiopathic disease.PubMedCrossRef

30.

• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–78 In this review, the authors highlight the ophthalmic complications of the newer chemotherapy agents, checkpoint inhibitors, including neuroretinitis.PubMedCrossRef

31.

Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect. 2016;6(1):14.PubMedPubMedCentralCrossRef

32.

Bajgai P, Katoch D, Dogra MR, Singh R. Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: clinical perspectives. Clin Ophthalmol. 2017;11:1805–17.PubMedPubMedCentralCrossRef

33.

Purvin V, Ranson N, Kawasaki A. Idiopathic recurrent neuroretinitis: effects of long-term immunosuppression. Arch Ophthalmol. 2003;121(1):65–7.PubMedCrossRef

34.

Purvin VA, Chioran G. Recurrent neuroretinitis. Arch Ophthalmol. 1994;112(3):365–71.PubMedCrossRef

35.

Sundaram SV, Purvin VA, Kawasaki A. Recurrent idiopathic neuroretinitis: natural history and effect of treatment. Clin Exp Ophthalmol. 2010;38(6):591–6.PubMedCrossRef

36.

Habot-Wilner Z, Zur D, Goldstein M, Goldenberg D, Shulman S, Kesler A, et al. Macular findings on optical coherence tomography in cat-scratch disease neuroretinitis. Eye (Lond). 2011;25(8):1064–8.CrossRef

37.

Stewart MW, Brazis PW, Barrett KM, Eidelman BH, Mendez JC. Optical coherence tomography in a case of bilateral neuroretinitis. J Neuroophthalmol. 2005;25(2):131–3.PubMedCrossRef

38.

Zatreanu L, Sibony PA, Kupersmith MJ. Optical coherence tomography in neuroretinitis: epipapillary infiltrates and retinal folds. J Neuroophthalmol. 2017;37(2):176–8.PubMedCrossRef

39.

Yamanuha JJYMM. Bartonella neuroretinitis: a case report with new insights from fundus autofluorescence. J Clin Exp Ophthalmol. 2014:445.

40.

Williams KE, Johnson LN. Neuroretinitis in patients with multiple sclerosis. Ophthalmology. 2004;111(2):335–40. discussion 40-1.PubMedCrossRef

41.

Parmley VC, Schiffman JS, Maitland CG, Miller NR, Dreyer RF, Hoyt WF. Does neuroretinitis rule out multiple sclerosis? Arch Neurol. 1987;44(10):1045–8.PubMedCrossRef

42.

Reddy AK, Morriss MC, Ostrow GI, Stass-Isern M, Olitsky SE, Lowe LH. Utility of MR imaging in cat-scratch neuroretinitis. Pediatr Radiol. 2007;37(8):840–3.PubMedCrossRef

43.

Schmalfuss IM, Dean CW, Sistrom C, Bhatti MT. Optic neuropathy secondary to cat scratch disease: distinguishing MR imaging features from other types of optic neuropathies. AJNR Am J Neuroradiol. 2005;26(6):1310–6.PubMed

44.

Breitschwerdt EB. Bartonellosis: one health perspectives for an emerging infectious disease. ILAR J. 2014;55(1):46–58.PubMedCrossRef

45.

• Habot-Wilner Z, Trivizki O, Goldstein M, Kesler A, Shulman S, Horowitz J, et al. Cat-scratch disease: ocular manifestations and treatment outcome. Acta Ophthalmol. 2018;96(4):e524–e32 Multicenter review of over 100 eyes that highlights the common ophthalmic manifestations of CSD. Additionally, the authors suggest antibiotics plus steriods improved acuity better than antibiotics alone.CrossRefPubMed

46.

Suhler EB, Lauer AK, Rosenbaum JT. Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis. Ophthalmology. 2000;107(5):871–6.PubMedCrossRef

47.

Reed JB, Scales DK, Wong MT, Lattuada CP Jr, Dolan MJ, Schwab IR. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology. 1998;105(3):459–66.CrossRefPubMed

48.

Gulati A, Yalamanchili S, Golnik KC, Lee AG. Cat scratch neuroretinitis: the role of acute and convalescent titers for diagnosis. J Neuroophthalmol. 2012;32(3):243–5.CrossRefPubMed

49.

Hage CA, Azar MM, Bahr N, Loyd J, Wheat LJ. Histoplasmosis: up-to-date evidence-based approach to diagnosis and management. Semin Respir Crit Care Med. 2015;36(5):729–45.PubMedCrossRef

50.

Bass JW, Freitas BC, Freitas AD, Sisler CL, Chan DS, Vincent JM, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J. 1998;17(6):447–52.PubMedCrossRef

51.

Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J. 1992;11(6):474–8.PubMedCrossRef

52.

Pitassi LH, Magalhaes RF, Barjas-Castro ML, de Paula EV, Ferreira MR, Velho PE. Bartonella henselae infects human erythrocytes. Ultrastruct Pathol. 2007;31(6):369–72.PubMedCrossRef

53.

Golnik KC, Marotto ME, Fanous MM, Heitter D, King LP, Halpern JI, et al. Ophthalmic manifestations of Rochalimaea species. Am J Ophthalmol. 1994;118(2):145–51.PubMedCrossRef

54.

Curi AL, Machado D, Heringer G, Campos WR, Lamas C, Rozental T, et al. Cat-scratch disease: ocular manifestations and visual outcome. Int Ophthalmol. 2010;30(5):553–8.CrossRefPubMed

55.

Bhatti MT, Lee MS. Should patients with bartonella neuroretinitis receive treatment? J Neuroophthalmol. 2014;34(4):412–6.PubMedCrossRef

56.

Conrad DA. Treatment of cat-scratch disease. Curr Opin Pediatr. 2001;13(1):56–9.PubMedCrossRef

57.

Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of Bartonellosis. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2017 [updated 05/07/2017. 1-5]. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/329/bartonellosis. Accessed 1 May 2019.

58.

Rosen BS, Barry CJ, Nicoll AM, Constable IJ. Conservative management of documented neuroretinitis in cat scratch disease associated with Bartonella henselae infection. Aust N Z J Ophthalmol. 1999;27(2):153–6.PubMedCrossRef

59.

Solley WA, Martin DF, Newman NJ, King R, Callanan DG, Zacchei T, et al. Cat scratch disease: posterior segment manifestations. Ophthalmology. 1999;106(8):1546–53.CrossRefPubMed

60.

Chi SL, Stinnett S, Eggenberger E, Foroozan R, Golnik K, Lee MS, et al. Clinical characteristics in 53 patients with cat scratch optic neuropathy. Ophthalmology. 2012;119(1):183–7.CrossRefPubMed

61.

Centers for Disease Control and Prevention - Bartonella infection (cat scratch disease, trench fever, and Carrión’s disease) 2014 [updated 12/14/2015]. Available from: https://www.cdc.gov/bartonella/clinicians/index.html. Accessed 1 May 2019.

62.

Attawan A, Pepper IM, Hickman SJ. The natural history of idiopathic neuroretinitis. Pract Neurol. 2015;15(5):387–8.PubMedCrossRef

63.

Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315(16):1767–77.PubMedCrossRef

64.

Centers for Disease Control and Prevention - Lyme disease 2018 [updated 12/21/2018. Available from: https://www.cdc.gov/lyme/treatment/index.html. Accessed 1 May 2019.

65.

Hu LT. Lyme disease. Ann Intern Med. 2016;164(9):ITC65–80.PubMedCrossRef

66.

Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690–5.PubMedCrossRef

67.

The diagnosis, management and prevention of syphilis: an update and review – a clinical guidance document for use in the diagnosis and management of syphilis. Based on content from the 2015 CDC STD treatment guidelines, and developed by the NYC Department of Health and Mental Hygiene Bureau of Sexually Transmitted Infections and the NYC STD Prevention Training Center. March 2019.

68.

Centers for Disease Control and Prevention - 2015 Sexually transmitted diseases treatment guidelines: Syphilis.2015.

69.

Arruga J, Valentines J, Mauri F, Roca G, Salom R, Rufi G. Neuroretinitis in acquired syphilis. Ophthalmology. 1985;92(2):262–70.PubMedCrossRef

70.

Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014;312(18):1905–17.PubMedPubMedCentralCrossRef

71.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95.PubMedPubMedCentralCrossRef

72.

American Thoracic S, Cdc, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR-11):1–77.

73.

Cutrufello NJ, Karakousis PC, Fishler J, Albini TA. Intraocular tuberculosis. Ocul Immunol Inflamm. 2010;18(4):281–91.PubMedCrossRef

74.

Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexler NA, Dumler JS, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. MMWR Recomm Rep. 2016;65(2):1–44.PubMedCrossRef

75.

Brett-Major DM, Coldren R. Antibiotics for leptospirosis. Cochrane Database Syst Rev. 2012;(2):CD008264.

76.

Todd SR, Dahlgren FS, Traeger MS, Beltran-Aguilar ED, Marianos DW, Hamilton C, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr. 2015;166(5):1246–51.PubMedCrossRef

77.

Gupta V, Gupta A, Rao NA. Intraocular tuberculosis--an update. Surv Ophthalmol. 2007;52(6):561–87.CrossRefPubMed

78.

Dreyer RF, Hopen G, Gass JD, Smith JL. Leber’s idiopathic stellate neuroretinitis. Arch Ophthalmol. 1984;102(8):1140–5.CrossRefPubMed

79.

Kirby JE. In vitro model of Bartonella henselae-induced angiogenesis. Infect Immun. 2004;72(12):7315–7.PubMedPubMedCentralCrossRef

80.

Cakir M, Cekic O, Bozkurt E, Pekel G, Yazici AT, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone acetonide injection for idiopathic neuroretinitis. Ocul Immunol Inflamm. 2009;17(3):221–3.PubMedCrossRef

81.

Empeslidis T, Banerjee S, Vardarinos A, Konstas AG. Dexamethasone intravitreal implant for idiopathic retinal vasculitis, aneurysms, and neuroretinitis. Eur J Ophthalmol. 2013;23(5):757–60.CrossRefPubMed

82.

Saatci AO, Ayhan Z, Takes O, Yaman A, Bajin FM. Single bilateral dexamethasone implant in addition to panretinal photocoagulation and oral azathioprine treatment in IRVAN syndrome. Case Rep Ophthalmol. 2015;6(1):56–62.PubMedPubMedCentralCrossRef

83.

Chong YJ, Logeswaran A, Sarmad A, Damato EM. Idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN): case series of three patients with multimodal imaging. Graefes Arch Clin Exp Ophthalmol. 2019;257(5):1013–8.PubMedCrossRef

84.

Cheema RA, Al-Askar E, Cheema HR. Infliximab therapy for idiopathic retinal vasculitis, aneurysm, and neuroretinitis syndrome. J Ocul Pharmacol Ther. 2011;27(4):407–10.CrossRefPubMed

85.

Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T. 2012;37(9):503–30.PubMedPubMedCentral

Titel: Treatment Strategies for Neuroretinitis: Current Options and Emerging Therapies
verfasst von: Aaron M. Fairbanks, MD
Matthew R. Starr, MD
John J. Chen, MD, PhD
M. Tariq Bhatti, MD
Publikationsdatum: 01.08.2019
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 8/2019
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-019-0579-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes

Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients

Interprofessional Care for Neuromuscular Disease

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials